Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake.

Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M, Polex-Wolf J, Lam BY, Zvetkova I, Pan W, Chiarugi D, Yeo GSH, Blouet C, Gribble FM, Reimann F. · 2019

Read Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake. by Adriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M, Polex-Wolf J, Lam BY, Zvetkova I, Pan W, Chiarugi D, Yeo GSH, Blouet C, Gribble FM, Reimann F. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6838660.txt.

Introduction

Adriaenssens and co-authors report a study in Cell Metabolism on a gut hormone and appetite. GIP is released after eating and is best known for prompting insulin release. Its role in weight gain has been muddled, since both boosting and blocking its receptor were reported to curb weight. Brain effects were suspected but the cells involved were unknown.

The team built mice whose GIP receptor cells could be marked and controlled. Such cells turned up in three appetite centres of the hypothalamus, in both mouse and human tissue. Gene reading split them into distinct clusters. Switching these brain cells on cut food intake. The work points to a central path for GIP's effect on eating.

Catalog record

CREATORAdriaenssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M, Polex-Wolf J, Lam BY, Zvetkova I, Pan W, Chiarugi D, Yeo GSH, Blouet C, Gribble FM, Reimann F.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE69 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6838660

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake By Alice E. Adriaenssens, Emma K. Biggs, Tamana Darwish, John Tadross, Tanmay Sukthankar, Milind Girish, Joseph Polex-Wolf, Brain Y. Lam, Ilona Zvetkova, Warren Pan, Davide Chiarugi, Giles S.H. Yeo Published in: Cell Metabolism DOI: 10.1016/j.cmet.2019.07.013 ABSTRACT Summary Ambiguity regarding the role of glucose-dependent insulinotropic polypeptide (GIP) in obesity arises from conflicting reports asserting that both GIP receptor (GIPR) agonism and antagonism are effective strategies for inhibiting weight gain. To enable identification and manipulation of Gipr-expressing (Gipr) cells, we created Gipr-Cre knockin mice. As GIPR-agonists have recently been reported to suppress food intake, we aimed to identify central mediators of this effect. Gipr cells were identified in the arcuate, dorsomedial, and paraventricular nuclei of the hypothalamus, as confirmed by RNAscope in mouse and human. Single-cell RNA-seq identified clusters of hypothalamic Gipr cells exhibiting transcriptomic signatures for vascular, glial, and neuronal cells, the latter expressing somatostatin but little pro-opiomelanocortin or agouti-related peptide. Activation of Gq-DREADDs in hypothalamic Gipr cells suppressed food intake in vivo, which was not obviously additive with concomitant GLP1R activation. These data identify hypothalamic GIPR as a target for the regulation of energy balance. CONTEXT AND SIGNIFICANCE Several drugs against diabetes and obesity are based on the gut hormone glucagon-like peptide-1 (GLP-1), which controls appetite and blood sugar levels. The related gut hormone glucose-dependent insulinotropic polypeptide (GIP) also controls blood glucose, but its role in food intake is debated. Researchers at the Institute of Metabolic Science in Cambridge, UK identified neurons expressing the GIP receptor in food intake control centers of mouse and human brain. Activating these neurons in mice reduced feeding, providing a neuronal circuit that could underlie the results of recent clinical trials of GLP-1-GIP dual agonist peptides, which suggested that GIP may work together with GLP-1 to suppress appetite. Understanding the role of this neuronal population responsive to GIP will help the development of new drugs targeting diabetes and obesity. INTRODUCTION Glucose-dependent insulinotropic polypeptide (GIP) is a gut hormone released from enteroendocrine cells in the duodenum and jejunum (Buchan et al., 1978, Buffa et al., 1975) within minutes of ingesting a meal (Elliott et al., 1993). GIP binds its cognate receptor, GIP receptor (GIPR)—a class B G-protein-coupled receptor (GPCR) (Usdin et al., 1993). GIPR activation stimulates insulin release in pancreatic beta cells (Dupre et al., 1973), and together with its sister incretin, glucagon-like peptide-1 (GLP-1), GIP is an important glucostat to keep post-prandial blood glucose levels in check. It is GLP-1, however that has enjoyed the therapeutic limelight in efforts to design more effective type 2 diabetes treatments. Initial interest in GIP-based therapies waned following studies showing that the insulinotropic properties of GIP are attenuated in patients with type 2 diabetes (Nauck et al., 1993). The complex relationship between GIP and adiposity has further obscured our understanding of GIP’s therapeutic potential. Studies showing that genetic or pharmacological blockade of GIPR protects against obesity have implicated GIP in promoting body weight gain (McClean et al., 2007, Miyawaki et al., 2002). These data are congruent with GIP’s role in facilitating triglyceride storage in adipose tissue (Eckel et al., 1979, Wasada et al., 1981). Though GIPR antagonists have inhibited weight gain in animal models (Boylan et al., 2015, Fulurija et al., 2008, Killion et al., 2018, McClean et al., 2007), the therapeutic utility of GIPR antagonism in humans is yet to be determined. The recent realization that some peptides designed to be GIPR antagonists exhibit partial agonist activity (Sparre-Ulrich et al., 2015), confounding the interpretation of some of these studies, as well as evidence indicating that the lipogenic action of GIP may be mediated indirectly via insulin (Campbell et al., 2016, Ugleholdt et al., 2011), has led some to question the rationale behind blocking GIP signaling as a route toward tackling obesity (Finan et al., 2016). Augmenting GIPR signaling in combination with proven antidiabetic agents has yielded exciting results. In rodents and humans, GLP-1-GIP dual agonism significantly improved glycemic control and provided greater body weight loss compared to treatment with a GLP-1 receptor agonist alone (Coskun et al., 2018, Finan et al., 2013, Frias et al., 2018, Nørregaard et al., 2018). In mice, this additional weight loss could be attributable to a further reduction in food intake (Coskun et al., 2018, Finan et al., 2013, Nørregaard et al., 2018). It is tempting to suggest that the addition of GIPR activation underlies the superior performance of these combinatorial therapies (Coskun et al., 2018, DiMarchi, 2018), although GIPR-only agonists appear to either not or fairly modestly reduce body weight when given in isolation (Coskun et al., 2018, Mroz et al., 2019). While GLP-1 exhibits central inhibitory actions on food intake (Turton et al., 1996), comparatively little is known about the central activity of GIP on appetite or the expression profile of Gipr in the CNS. Previous attempts at visualizing the localization of Gipr in the CNS relied on traditional in situ hybridization or radiolabeled ligands (Kaplan and Vigna, 1994, Paratore et al., 2011, Usdin et al., 1993). While these studies did find evidence of Gipr in the cortex, hippocampus, and olfactory bulb, the low resolution of these methodologies does not allow for the precise mapping of Gipr production to distinct cells. In this study, we sought to define the central GIP signaling axis and to understand how manipulation of Gipr cells in the brain affects feeding behavior. Through the use of a transgenic mouse, Gipr-Cre, we examined the location, transcriptomic profile, and effects of acute activation of Gipr cells in the CNS. RESULTS Gipr Is Expressed in Neurons and Glial Cells in Key Feeding Centers of the Brain Although two GIPR antagonistic antibodies have been reported (Killion et al., 2018, Ravn et al., 2013), neither has been used for immunohistochemical localization. To label Gipr cells, we generated a knockin transgenic mouse model (Gipr-Cre) in which Cre-recombinase replaces the Gipr coding sequence, enabling the genetic and chemogenetic manipulation of Gipr cells; mice homozygous for Gipr-Cre are thus Gipr nulls. Gipr null offspring were protected against body weight gain when subjected to a high-fat diet (HFD) for 17 weeks and had significantly lower percent fat mass compared with Gipr-Cre heterozygous and wild-type (WT) littermates (Figures S1A and S1B), supporting previous results from another Gipr knock-out (KO) model (Miyawaki et al., 2002). Heterozygous Gipr-Cre mice, by contrast, gained a similar amount of weight as WT mice, despite reduced Gipr expression due to haploinsufficiency (Figure S1C). For the rest of this study, we used Gipr-Cre heterozygous animals. By crossing Gipr-Cre mice with ROSA26-EYFP reporter mice (GiprEYFP), we identified Gipr cells in target tissues. Staining for EYFP in the pancreas of GiprEYFP mice reported expression of Gipr in both alpha and beta cells, as expected. Heterogeneous EYFP staining was also found in the surrounding pancreatic exocrine tissue (Figures S1D and S1E). A proportion of adipocytes in interscapular brown and inguinal white adipose tissue stained positively for EYFP (Figures S1F and S1G). These data provided confidence that the Gipr-Cre transgene successfully targets Gipr expressing cells, as they are consistent with known expression patterns for Gipr (Campbell and Drucker, 2013). To create a map of central Gipr localization, brains of GiprEYFP mice were serially sectioned and stained

Read the complete text